277 related articles for article (PubMed ID: 36864522)
21. Predicting the prognosis, immune response, and immunotherapy in head and neck squamous cell carcinoma using a novel risk model based on anoikis-related lncRNAs.
Deng H; Wei Z; Du J; Shen Z; Zhou C
Eur J Med Res; 2023 Nov; 28(1):548. PubMed ID: 38017579
[TBL] [Abstract][Full Text] [Related]
22.
Wei Z; Shen Y; Zhou C; Cao Y; Deng H; Shen Z
Bioengineered; 2022 May; 13(5):13784-13800. PubMed ID: 35712757
[TBL] [Abstract][Full Text] [Related]
23. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
Yang L; Yu J; Tao L; Huang H; Gao Y; Yao J; Liu Z
Front Genet; 2022; 13():947551. PubMed ID: 35938003
[No Abstract] [Full Text] [Related]
24. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
[TBL] [Abstract][Full Text] [Related]
25. Interferon Regulatory Factor Family Genes: At the Crossroads between Immunity and Head and Neck Squamous Carcinoma.
Liu S; Wang Z
Dis Markers; 2022; 2022():2561673. PubMed ID: 35664436
[TBL] [Abstract][Full Text] [Related]
26. Constructing a prognostic model for head and neck squamous cell carcinoma based on glucose metabolism related genes.
Liu Y; Liu N; Zhou X; Zhao L; Wei W; Hu J; Luo Z
Front Endocrinol (Lausanne); 2023; 14():1245629. PubMed ID: 37876534
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the immune cell function landscape in head and neck squamous carcinoma to assist in prognosis prediction and immunotherapy.
Wang W; Zhang Z; Li W; Wei D; Xu J; Qian Y; Cao S; Lei D
Aging (Albany NY); 2023 Nov; 15(21):12588-12617. PubMed ID: 37955651
[TBL] [Abstract][Full Text] [Related]
28. DKK1 affects survival of patients with head and neck squamous cell carcinoma by inducing resistance to radiotherapy and immunotherapy.
Ye X; Liu J; Quan R; Lu Y; Zhang J
Radiother Oncol; 2023 Apr; 181():109485. PubMed ID: 36690301
[TBL] [Abstract][Full Text] [Related]
29. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
30. Expression and prognostic analysis of BGN in head and neck squamous cell carcinoma.
Zhao L; Liang J; Zhong W; Han C; Liu D; Chen X
Gene; 2022 Jun; 827():146461. PubMed ID: 35358652
[TBL] [Abstract][Full Text] [Related]
31. Identification of genetic mechanisms underlying lipid metabolism-mediated tumor immunity in head and neck squamous cell carcinoma.
Liu S; Wang S; Wang Z
BMC Med Genomics; 2023 May; 16(1):110. PubMed ID: 37210507
[TBL] [Abstract][Full Text] [Related]
32. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
33. Identification of Gene-Tyrosine Kinase 2 (TYK2) in Head and Neck Squamous Cell Carcinoma Patients-An Integrated Bioinformatics Approach.
Gong X; Ren F
Dis Markers; 2022; 2022():5239033. PubMed ID: 35711568
[TBL] [Abstract][Full Text] [Related]
34. DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma.
Li R; Wen X; Lv RX; Ren XY; Cheng BL; Wang YK; Chen RZ; Hu W; Tang XR
Cell Oncol (Dordr); 2024 Feb; ():. PubMed ID: 38315286
[TBL] [Abstract][Full Text] [Related]
35. Profiles of immune cell infiltration in head and neck squamous carcinoma.
Liang B; Tao Y; Wang T
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32095823
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptors signature reveal the head and neck squamous cell carcinoma energy metabolism phenotype and clinical outcome.
Yao Y; Wang D; Zhang Y; Tang Q; Xu Z; Qin L; Qu Y; Yan Z
J Gene Med; 2024 Jan; 26(1):e3605. PubMed ID: 37932968
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
38. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
40. 5-Methylcytosine-related lncRNAs: predicting prognosis and identifying hot and cold tumor subtypes in head and neck squamous cell carcinoma.
Huang J; Xu Z; Zhou C; Cheng L; Zeng H; Shen Y
World J Surg Oncol; 2023 Jun; 21(1):180. PubMed ID: 37312123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
